BUSINESS
    Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
    By Kimi Orita August 31, 2026
    Recordati Rare Diseases Japan President Shoji Kuroyama has called on Japan to revisit a pricing rule that wipes out premiums when drug makers disclose less than 50% of the manufacturing costs of new medicines priced…

    LATEST

    Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
    August 31, 2026
    Sumitomo Pharma is aiming for 100 billion yen in annual sales from its adjuvant supply business from FY2030 onward as it looks to establish the technology as a long-term revenue source and expand globally through…
    Shionogi to Get US$36.9 Million as US Govt Procures Fetroja
    August 31, 2026
    Shionogi said on August 28 that the US government has exercised an option to procure its antibiotic cefiderocol, marketed as Fetroja, under a contract signed in April, triggering a US$36.9 million payment to the company.The…
    Daiichi’s CD25-Directed ADC DS1025 Enters Clinic
    August 31, 2026
    Daiichi Sankyo said on August 27 that the first patient has been dosed in a first-in-human PI trial of its novel CD25-directed antibody drug conjugate (ADC) DS1025 in advanced or metastatic solid tumors.The global study…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COLUMN

    The One Mistake on Your Resume
    By Philip Carrigan

    We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

    COMMENTARY

    Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
    By Shinya Sato

    More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA